Efficacy of therapy in patients with newly diagnosed myelodysplastic syndrome with unfavorable immunophenotypic and cytogenetic prognosis

dc.contributor.author	Trubkina, H.
dc.contributor.author	Iskrou, I.
dc.contributor.author	Lendzina, I.
dc.contributor.author	Lebedeva, T.
dc.contributor.author	Smolnikova, V.
dc.date.accessioned	2025-06-16T13:08:24Z
dc.date.available	2025-06-16T13:08:24Z
dc.date.issued	2023
dc.identifier.uri	https://rep.bsmu.by/handle/BSMU/49403
dc.description	Efficacy of therapy in patients with newly diagnosed myelodysplastic syndrome with unfavorable immunophenotypic and cytogenetic prognosis / H. Trubkina, I. Iskrou, I. Lendzina [et al.] // HemaSphere. – 2023. – Vol. 7, suppl. 3 [EHA 2023 : 28th Hybrid Congr. of the Europ. Hematology Assoc., Frankfurt, 8-15 June 2023 : Abstr. book]. – P. 3901–3902. – URL: https://journals.lww.com/hemasphere/Documents/EHA2023%20Abstract%20Book.pdf	ru_RU
dc.language.iso	en	ru_RU
dc.title	Efficacy of therapy in patients with newly diagnosed myelodysplastic syndrome with unfavorable immunophenotypic and cytogenetic prognosis	ru_RU
dc.type	Article	ru_RU